

# Datasheet: MCA2806SBY575

**BATCH NUMBER 100007244**

<b>Description:</b>	MOUSE ANTI HUMAN CD69:StarBright Yellow 575
<b>Specificity:</b>	CD69
<b>Other names:</b>	AIM
<b>Format:</b>	StarBright Yellow 575
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	FN50
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	100 TESTS/0.5ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human								
Species Cross Reactivity	Reacts with: Baboon, Chimpanzee, Cynomolgus monkey, Rhesus Monkey, Macaque <b>N.B.</b> Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.								
Product Form	Purified IgG conjugated to StarBright Yellow 575 - liquid								
Max Ex/Em	<table><tr><th>Fluorophore</th><th>Excitation Max (nm)</th><th>Emission Max (nm)</th></tr><tr><td>StarBright Yellow 575</td><td>548</td><td>579</td></tr></table>	Fluorophore	Excitation Max (nm)	Emission Max (nm)	StarBright Yellow 575	548	579		
Fluorophore	Excitation Max (nm)	Emission Max (nm)							
StarBright Yellow 575	548	579							
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant								

<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> ) 1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350 0.05% Tween 20
<b>Immunogen</b>	Activated human B-cells.
<b>External Database Links</b>	<b>UniProt:</b> <a href="#">Q07108</a> <a href="#">Related reagents</a>  <b>Entrez Gene:</b> <a href="#">969</a> CD69 <a href="#">Related reagents</a>
<b>Synonyms</b>	CLEC2C
<b>Specificity</b>	<p><b>Mouse anti Human CD69 antibody, clone FN50</b> recognizes the human early activation antigen CD69, also known as activation inducer molecule (AIM), Early T-cell activation antigen p60, EA1 or MLR-3. CD69 is a 199 amino acid single pass type II transmembrane glycoprotein of ~30 kDa containing a single <a href="#">C-type lectin domain</a> and a single potential <a href="#">N-glycosylation site</a>. CD69 is expressed as a disulphide bond linked homodimer of ~60 kDa (<a href="#">López-Cabrera et al. 1993</a>).</p> <p>CD69 is a marker of early activation expressed by B and T lymphocytes, natural killer cells(<a href="#">Werfel 1997</a>), neutrophils, thymocytes and platelets (<a href="#">Gaviol et al. 1992</a>). Expression of CD69 is rapidly induced on activation by infection or chronic inflammation (<a href="#">Sancho et al. 2005</a>). Multiple dimeric glycoforms of CD69 can be formed through differential glycosylation of the monomeric subunits (<a href="#">Vance et al. 1997</a>).</p> <p>Mouse anti Human CD69 , clone FN50 is useful for the detection of CD69 by flow cytometry and immunohistochemistry on frozen tissue sections.</p>
<b>Flow Cytometry</b>	Use 5ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
<b>References</b>	<ol style="list-style-type: none"> <li>Holte, H. <i>et al.</i> (1989) Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. <a href="#">Int J Cancer. 44 (6): 975-80.</a></li> <li>Herberth, M. <i>et al.</i> (2010) Differential effects on T-cell function following exposure to serum from schizophrenia smokers. <a href="#">Mol Psychiatry. 15 (4): 364-71.</a></li> <li>Schaeuble, K. <i>et al.</i> (2011) Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. <a href="#">J Immunol. 187 (11): 5645-52.</a></li> <li>Sela, M. <i>et al.</i> (2011) Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells. <a href="#">EMBO J. 30 (15): 3160-72.</a></li> <li>Garbe, Y. <i>et al.</i> (2011) Semiallogenic fusions of MSI(+) tumor cells and activated B cells</li> </ol>

- induce MSI-specific T cell responses. [BMC Cancer. 11: 410.](#)
6. Schwitalle, Y. *et al.* (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. [Cancer Immun. 4: 14.](#)
7. Sutavani, R.V. *et al.* (2013) CD55 Costimulation Induces Differentiation of a Discrete T Regulatory Type 1 Cell Population with a Stable Phenotype. [J Immunol. 191: 5895-903.](#)
8. Walter, G.J. *et al.* (2013) Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells. [Arthritis Rheum. 65: 627-38.](#)
9. Kuric, E. *et al.* (2017) Demonstration of Tissue Resident Memory CD8 T Cells in Insulinitic Lesions in Adult Patients with Recent-Onset Type 1 Diabetes. [Am J Pathol. 187 \(3\): 581-8.](#)
10. Karnell, F.G. *et al.* (2017) Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. [Clin Exp Immunol. 189 \(3\): 268-278.](#)
11. Rossatti, P. *et al.* (2022) Rapid increase in transferrin receptor recycling promotes adhesion during T cell activation. [BMC Biol. 20 \(1\): 189.](#)

<b>Storage</b>	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA2806SBY575">https://www.bio-rad-antibodies.com/SDS/MCA2806SBY575</a> 20471
<b>Regulatory</b>	For research purposes only

## Related Products

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M413689:221125'

Printed on 11 Jul 2024